Targeting Non-Apoptotic Pathways with the Cell Permeable TAT-Conjugated NOTCH1 RAM Fragment for Leukemia and Lymphoma...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Apoptosis resistance is a major challenge in cancer therapy, particularly in leukemia and lymphomas.
• Targeting nonapoptotic cell death pathways presents a promising alternative strategy.
• NOTCH1 signaling plays a role in T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis.

Purpose of the Study:

• To develop and evaluate Tat-Ram13, a novel peptide for targeting nonapoptotic cell death in refractory leukemia and lymphomas.
• To investigate the mechanism of action and cell selectivity of Tat-Ram13.

Main Methods:

• Development of Tat-Ram13, a peptide combining RAM13 (NOTCH1 intracellular domain fragment) and HIV-1 TAT.
• Assessment of Tat-Ram13's effects on NOTCH1-target genes and cell viability in various cancer cell lines and normal lymphocytes.
• Investigation of the cell death mechanism, including macropinocytosis, mitochondrial membrane potential, and caspase/PARP-1 activation.
• Alanine scanning mutagenesis to identify critical residues for cytotoxicity.

Main Results:

• Tat-Ram13 significantly downregulated NOTCH1-target genes in T-ALL cell lines.
• The peptide exhibited potent, selective cytotoxicity against human leukemia and lymphoma cell lines, sparing normal lymphocytes.
• Cell death was mediated by macropinocytosis, mitochondrial depolarization, and plasma membrane rupture, independent of caspase-3 or PARP-1 activation.
• Four critical hydrophobic amino acids in the RAM13 domain were identified as essential for Tat-Ram13's cytotoxicity.

Conclusions:

• Tat-Ram13 is a novel peptide that induces selective nonapoptotic cell death in leukemia and lymphoma cells.
• It represents a potential therapeutic agent for apoptosis-resistant hematological malignancies.
• The findings highlight the therapeutic potential of targeting nonapoptotic cell death pathways.